Including SAB’s polyclonal therapy in NIAID COVID study could yield shield against variants

NIH has picked SAB’s antibody therapy as the latest addition to its master protocol trial to treat COVID-19 outpatients. As a polyclonal therapy, SAB-185 could offer greater resilience to emerging viral variants than mAbs, including those already authorized for the indication.

NIH’s National Institute of Allergy and Infectious Diseases announced Wednesday it has begun enrolling mild-to-moderate patients in the Phase II/III ACTIV-2 study arm testing IV SAB-185 from SAB Biotherapeutics Inc...